Technology
Health
Biotechnology

Neuralstem

$0.5051
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.094 (-15.69%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell Neuralstem and other stocks, options, ETFs, and crypto commission-free!

About

Neuralstem, Inc. Common Stock, also called Neuralstem, is a biopharmaceutical company, which engages in the research, development, and commercialization of central nervous system therapies based on human neuronal stem cells and small molecule compounds. Read More Its pipeline includes NSI-189 small molecule program, NSI-566 stem cell therapy program, and novel and proprietary chemical entity screening platform. The company was founded by I. Richard Garr, Karl Y. Johe, and Merrill Solomon in 1996 and is headquartered in Germantown, MD.

Employees
6
Headquarters
Germantown, Maryland
Founded
1996
Market Cap
9.11M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
174.59K
High Today
$0.60
Low Today
$0.48
Open Price
$0.60
Volume
210.49K
52 Week High
$2.05
52 Week Low
$0.2502

Collections

Technology
Health
Biotechnology
Biopharmaceutical
Therapy
Pharmaceutical
US
North America

News

Markets InsiderMar 22

Neuralstem Reports Year End 2018 Fiscal Results

GERMANTOWN, Md., March 22, 2019 (GLOBE NEWSWIRE) -- Neuralstem, Inc. (Nasdaq: CUR), a biopharmaceutical company focused on the development of nervous system therapies based on its neural stem cell and small molecule technologies, today reported its financial results for the year ended December 31, 2018. Financial Results for the Year Ended December 31, 2018 Cash Position and Liquidity: At December 31, 2018, cash and investments was approximately $5.8 million as compared to approximately $11.7 million fo...

155
MarketBeatMar 6

Stock Price, News, & Analysis for Neuralstem

Neuralstem, Inc., a clinical stage biopharmaceutical company, focuses on the research and development of nervous system therapies based on its proprietary human neuronal stem cells and small molecule compounds. The company's stem cell based technology enables the isolation and expansion of human neural stem cells from various areas of the developing human brain and spinal cord enabling the generation of physiologically relevant human neurons of various types. Its lead product candidate is NSI-189, a chemica...

223

Earnings

-$0.73
-$0.49
-$0.24
$0.00
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
Actual
Available Mar 22, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.